No systemic toxicities were found in rat and dog studies at dosages equivalent to 10 times normal human exposure L2469. It is thought that the risk of toxicity is low due to the short duration of action and short half life of atosiban A32685.
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Isoetharine | The risk or severity of adverse effects can be increased when Isoetharine is combined with Atosiban. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with Atosiban. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Atosiban. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with Atosiban. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with Atosiban. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with Atosiban. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with Atosiban. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with Atosiban. |
| Bitolterol | The risk or severity of adverse effects can be increased when Bitolterol is combined with Atosiban. |
| Salmeterol | The risk or severity of adverse effects can be increased when Salmeterol is combined with Atosiban. |
| Formoterol | The risk or severity of adverse effects can be increased when Formoterol is combined with Atosiban. |
| Albuterol | The risk or severity of adverse effects can be increased when Salbutamol is combined with Atosiban. |
| Isoprenaline | The risk or severity of adverse effects can be increased when Isoprenaline is combined with Atosiban. |
| Arbutamine | The risk or severity of adverse effects can be increased when Arbutamine is combined with Atosiban. |
| Arformoterol | The risk or severity of adverse effects can be increased when Arformoterol is combined with Atosiban. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Atosiban. |
| Pirbuterol | The risk or severity of adverse effects can be increased when Pirbuterol is combined with Atosiban. |
| Ephedra sinica root | The risk or severity of adverse effects can be increased when Ephedra sinica root is combined with Atosiban. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with Atosiban. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with Atosiban. |
| Bambuterol | The risk or severity of adverse effects can be increased when Bambuterol is combined with Atosiban. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with Atosiban. |
| Indacaterol | The risk or severity of adverse effects can be increased when Indacaterol is combined with Atosiban. |
| Droxidopa | The risk or severity of adverse effects can be increased when Droxidopa is combined with Atosiban. |
| Protokylol | The risk or severity of adverse effects can be increased when Protokylol is combined with Atosiban. |
| Hexoprenaline | The risk or severity of adverse effects can be increased when Hexoprenaline is combined with Atosiban. |
| Olodaterol | The risk or severity of adverse effects can be increased when Olodaterol is combined with Atosiban. |
| Vilanterol | The risk or severity of adverse effects can be increased when Vilanterol is combined with Atosiban. |
| Doxofylline | The risk or severity of adverse effects can be increased when Doxofylline is combined with Atosiban. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with Atosiban. |
| Etafedrine | The risk or severity of adverse effects can be increased when Etafedrine is combined with Atosiban. |
| PF-00610355 | The risk or severity of adverse effects can be increased when PF-00610355 is combined with Atosiban. |
| Abediterol | The risk or severity of adverse effects can be increased when Abediterol is combined with Atosiban. |
| Batefenterol | The risk or severity of adverse effects can be increased when Batefenterol is combined with Atosiban. |
| Levosalbutamol | The risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atosiban. |